Katherine Bowdish, Ph.D.
Vice President Global R&D and Head of Sunrise, Sanofi U.S.
Katherine Bowdish is Vice President of Global R&D and Head of Sunrise at Sanofi. Katherine joined Sanofi in February 2013 to launch the Sunrise initiative following extensive experience in co-founding and leading early-stage biotechnology companies, driving the science as well as transactions involving financings, partnering and M&A.
Katherine led Cambridge-based Permeon Biologics, developing a novel approach to intracellular delivery of biological therapies as its President and CSO. Prior to taking the helm at Permeon, Katherine co-founded and served as President and CEO of Anaphore (now RuiYi), a platform-based drug development company with a focus on trivalent biological therapies. Katherine was previously President of Alexion Antibody Technologies, Inc., and Senior Vice President of Alexion Pharmaceuticals upon leading the acquisition of Prolifaron by Alexion. She was the founder, CEO and CSO of Prolifaron, a privately held antibody discovery company. In earlier years, Katherine worked with Richard A. Lerner, M.D., at The Scripps Research Institute on catalytic antibodies and related antibody technologies, and at Monsanto in agricultural biotechnology. She received her doctorate from Columbia University College of Physicians and Surgeons and her bachelor’s degree from the College of William and Mary.
Katherine represents Sanofi on the Boards of Directors of three Sunrise portfolio companies, including Warp Drive Bio and MyoKardia.